Splenic infarction and bevacizumab

Details

Request a copyRequest a copy
Serval ID
serval:BIB_22CB2287495D
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Production externe
Title
Splenic infarction and bevacizumab
Journal
Lancet Oncol
Author(s)
Malka D., Van den Eynde M., Boige V., Dromain C., Ducreux M.
ISSN-L
1470-2045 (Print)1470-2045 (Linking)
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
7
Number
12
Pages
1038
Language
english
Notes
Malka, DavidVan den Eynde, MarcBoige, ValerieDromain, ClarisseDucreux, MichelengCase ReportsEngland2006/12/02 09:00Lancet Oncol. 2006 Dec;7(12):1038.
Keywords
Adenocarcinoma/*drug therapy/secondary, Angiogenesis Inhibitors/*adverse effects, Antibodies, Monoclonal/*adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Bevacizumab, Humans, Male, Middle Aged, Splenic Infarction/*etiology/pathology, Vascular Endothelial Growth Factor A/metabolism
DOI
10.1016/S1470-2045(06)70980-9
Publisher's website
http://www.ncbi.nlm.nih.gov/pubmed/17138227
Create date
16/09/2016 11:14
Last modification date
20/08/2019 14:00
Usage data